In this episode, host Shikha Jain, MD, speaks with David Gandara, MD, about how ctDNA and CAR-T cell therapies are transforming precision medicine, the importance of patient reported outcomes and more.

•    Welcome to another exciting episode of Oncology Overdrive 0:14
•    About Gandara 0:19
•    The interview 1:02
•    Can you tell me a little more about what you are working on now? 1:25
•    How did you get engaged with the community in Hawaii?  6:30
•    What do you think is going to happen with ctDNA moving forward? 8:29
•    Can you utilize ctDNA and minimal residual disease information to determine how long patients need to be on adjuvant therapy?  11:42
•    How did you get into the ctDNA space?  15:06
•    How do you see AI transforming health care beyond providing patients with more information and taking more ownership of their health?  18:28
•    Can you tell us more about how a second opinion clinic works? How did this type of clinic develop and become part of what you do?  23:17
•    What are some of your predictions as to what will happen in oncology care over the next ten to twenty years?  29:00
•    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 37:30
•    How to contact Gandara 38:47
•    Thanks for listening 39:10

David Gandara, MD, is a clinician-scientist and lung cancer specialist internationally recognized for his expertise in thoracic cancers, cancer drug development and biomarker development.

We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Dr. Gandara can be reached via email drgandara@ucdavis.edu. 

Disclosures: Jain reports no relevant financial disclosures. Gandara reports institutional research grants from Astex, Amgen and Genentech; institutional consulting for AstraZenica, Exact Sciences, Genentech, Guardant Health, IO Biotech and Oncohost; consulting for Adagene, Henlius USA, Foundation Medicine and Sanofi; serves on the advisory board of Abbvie, Janssen, Merck, Mirati, Regeneron and Revolution Medicine.